- U.S.
Drug Enforcement Agency’s (DEA) decision to remove certain CBD products
from its Schedule 1 list of controlled substances will make CBD clinical
studies easier to plan
- ETST’s
pipeline includes CBD-based pharmaceutical formulas; company expects its
pure hemp oil and new formulas to eventually be sold worldwide
- ETST
will be a licensed distributor and plans to work closely with pharmacists
and researchers to serve this market; it plans to launch two CBD
nutraceutical formulas
Earth Science Tech, Inc.’s (OTCQB: ETST) anticipation that
its pure hemp oil and new formulas will eventually be sold globally and that it
will be a licensed distributor and will work closely with pharmacists and
researchers to serve the cannabis market has been strengthened by the DEA’s
recent decision on CBD (http://ibn.fm/47mHo).
The DEA decided to remove some CBD products from its
Schedule 1 list of controlled substances. It voted to reclassify FDA-approved
drugs that contain cannabis-derived CBD and contain less than 0.1%
tetrahydrocannabinol (THC) as Schedule V, the lowest restriction
classification.
ETST sees this ruling as an opportunity. In a news release,
Dr. Michel Aubé, CEO and chief science officer of ETST, said, “In 2018, we have
a much deeper understanding of cannabinoids, cannabinoid-receptors, and the
endocannabinoid system than we did decades ago when CBD was classified as a
schedule 1 drug. We are pleased to see that the DEA has shifted its stance amid
conclusive evidence that CBD is not addictive but has both anti-psychotic
properties and the opposite effect of THC.”
ETST is a biotech company based in Doral, Florida, marketing
and developing CBD products for the pharmaceutical and nutraceutical fields.
The company is focused on the cannabidiol, pharmaceutical and nutraceutical
sectors, as well as the development, through subsidiaries, of medical devices
and research. ETST’s goal is to become a world leader in the CBD space.
ETST has announced that it will soon launch two CBD-based
nutraceutical formulas under a provisory patent. These include a neuron
protector and a breast protector. The company is also developing a new brand
for these formula patents.
The company said that the Quebec Agrifood Innovation Center
(QAIC) is completing the standardization of the formulas. By the end of
October, TransBiotech is expected to conduct in vitro testing of the biological
activities of the formula, comparing the level of protection offered by ETST’s
hemp oil alone versus its hemp oil with other natural ingredients.
Nickolas S. Tabraue, president and director of ETST, added,
“The results obtained from TransBiotech will help us understand the mechanism
of action of CBD and will open the doors for the research needed to develop
revolutionary CBD-based pharmaceutical drugs.”
ETST holds several wholly owned subsidiaries. Cannabis
Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures
and distributes in the recreational sector. Earth Science Foundation, Inc. is
becoming a non-profit and accepts grants and donations to conduct additional
studies. Earth Science Pharmaceutical develops medical diagnostic tools and
vaccines. ETST also formed subsidiary Canno Inno Laboratories Inc., a strategic
Montreal, Canada-based company that provides ETST with access to government
grants.
For more information, visit the company’s website at www.EarthScienceTech.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
